Nalaganje...
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in 2015 for stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism. It is the fourth target-specific oral anticoagulant to be approved. Edoxaban is noninferior for ef...
Shranjeno v:
| izdano v: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4853158/ https://ncbi.nlm.nih.gov/pubmed/27217759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S84608 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|